×
About 228 results

ALLMedicine™ Acetylcholine Receptor Antibody Center

Research & Reviews  86 results

Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic bi...
https://doi.org/10.1002/mus.27381
Muscle & Nerve; Lee I, Sanders D

Jul 22nd, 2021 - Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic biomarker for myasthenia gravis.|2021|Lee I,Sanders D,|

The use of eculizumab in ventilator-dependent myasthenia gravis patients.
https://doi.org/10.1002/mus.27326
Muscle & Nerve; Usman U, Chrisman C et. al.

May 20th, 2021 - Eculizumab has been shown to be efficacious in acetylcholine receptor antibody-positive (AChR+ ) Myasthenia Gravis Foundation of America (MGFA) class II, III, and IV generalized myasthenia gravis (gMG) patients. However, it has not been studied in...

Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis:...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084046
Medicine Liu C, Liu P et. al.

Apr 29th, 2021 - To evaluate the efficacy of double-filtration plasmapheresis (DFPP) treatment of myasthenia gravis (MG) through a systematic review and meta-analysis. PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Chinese Scient...

Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis out...
https://doi.org/10.1136/jnnp-2020-325511
Journal of Neurology, Neurosurgery, and Psychiatry; Kojima Y, Uzawa A et. al.

Mar 27th, 2021 - To investigate the association between changes in anti-acetylcholine receptor antibody (AChR Ab) levels induced by immunosuppressive treatment and myasthenia gravis (MG) prognosis at 1-year post-treatment in patients with MG. We included 53 consec...

Correlation of anti-γ/ε nicotinic acetylcholine receptor antibody levels with anti-desm...
https://doi.org/10.1111/ced.14645
Clinical and Experimental Dermatology; Toosi R, Teymourzadeh A et. al.

Mar 14th, 2021 - A role for nondesmoglein antigens in the pathogenesis of pemphigus vulgaris (PV) has been suggested in several studies. Acetylcholine receptors (AchR), are one of the most important groups of these antigens. However, the exact role of both antimus...

see more →

Clinicaltrials.gov  1 results

Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
https://clinicaltrials.gov/ct2/show/NCT03350659

Apr 5th, 2019 - Visit 1. Enroll, baseline evaluation of the patients Questionnaire Evaluate orthostatic hypotension symptom: Orthostatic Hypotension Questionnaire (OHQ) Quality of life: Korean version of Short-form 36 Depressive symptom: Korean version of Beck De...

see more →

News  4 results

Potential First-in-Class, Targeted Therapy for Myasthenia Gravis
https://www.medscape.com/viewarticle/953330

Jun 17th, 2021 - Efgartigimod (argenx) is an effective and well-tolerated therapy for patients with generalized myasthenia gravis (gMG), new research suggests. Results from the phase 3, randomized, placebo-controlled ADAPT trial showed that reduction in disease bu...

Placebo response in negative rituximab BeatMG trial provides important lessons
https://www.mdedge.com/clinicalneurologynews/article/210310/neuromuscular-disorders/placebo-response-negative-rituximab/page/0/1?channel=39313

Oct 17th, 2019 - Suggestions from the data The post hoc subgroup analysis should be interpreted with caution, and the study does not provide firm conclusions, Dr. Nowak noted.

Cognitive Impairment and Autonomic Ganglionopathy
https://www.medscape.com/viewarticle/764741

Jun 5th, 2012 - Autoimmune Autonomic Ganglionopathy With Reversible Cognitive Impairment Gibbons CH, Centi J, Vernino S, Freeman R Arch Neurol. 2012;69:461-466 Study Summary Autoimmune autonomic ganglionopathy (AAG) is a rare form of severe autonomic failure link...

Myasthenia gravis therapy: Immunoadsorbent may eliminate need for plasma products
https://www.mdedge.com/ccjm/article/92699/myasthenia-gravis-therapy-immunoadsorbent-may-eliminate-need-plasma-products

Abstract This in vitro study assessed the effectiveness of a new immunoadsorbent (Asahi IM-TR 350) in removing anti-acetylcholine receptor antibody from plasma with minimal loss of albumin. Plasma procured from a myasthenia gravis patient undergoi.

see more →